Moxifloxacin is a quinolone antibacterial  agent (fluoroquinolones).

Moxifloxacin inhibits bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) that are required for bacterial DNA replication, transcription and repair.

Moxifloxacin is indicated for the treatment of community acquired pneumonia (CAP), complicated skin and skin structure infections (cSSSI).

Moxifloxacin should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.
Active ingredient Pharmaceutical form Package Therapeutic target
  • Moxifloxacin
  • Ophth. Sol.
  • F.c. Tablets
  • Sol. for Infusion
  • 0,5%
  • 400mg
  • 400mg/250ml
  • Antibiotic

Other products in "International"